Jones Trading on Praxis Precision Medicines Inc. (PRAX): 'one step closer to becoming a commercial-stage company'

April 14, 2026 3:32 PM

Jones Trading analyst Justin Walsh reiterated a Buy rating and $441.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX)The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found